A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases

• Published in: BMC cancer 2022-04, Vol.22 (1), p.415-9, Article 415
• Main Authors: Myint, Zin W, El Khouli, Riham, Lemieux, Bryan, Yan, Donglin, St Clair, William H, Liu, Xiaoqi, Kunos, Charles A
• Format: Article
• Language: English
• Subjects: Analgesic consumption; Analgesics; Androgens; Antitumor agents; Bone marrow; Bone Neoplasms - secondary; Bone pain; Bone seeking radionuclides; Cancer Pain - drug therapy; Cancer Pain - etiology; Cancer therapies; Care and treatment; Castration; Diagnosis; Diethylenetriaminepentaacetic acid; Dosage and administration; Dosimetry; Drug dosages; Humans; Male; Metastases; Metastasis; Metastatic castration resistant prostate cancer with bone met; Pain; Pain response; Palliation; Patient reported outcome; Patients; Pentetic Acid; Pharmaceuticals; Population studies; Prevention; Prospective Studies; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - drug therapy; Radiation therapy; Radioisotopes; Radium; Radium - adverse effects; Response rates; Risk factors; Scintigraphy; Study Protocol; Survival; Testing; Testosterone; Toxicity; Tumors
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09496-2

Several bone-seeking radionuclides have been developed for palliation of metastatic bone pain since 1956, however, so far radium-223 dichloride is the first and only Food and Drug Administration (FDA) approved targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) based on ALSYMPCA phase 3 study. While radium-223 does improve pain and overall survival outcomes, the improvement can come at the expense of side effects such as bone marrow toxicity. The development of new and better treatment with long-standing pain relief is clearly an unmet medical need. The study is a non-randomized phase II study. The study population consists of 25 patients with CRPC who had progressed on any lines of prior therapies and whose serum testosterone level is less than 50 ng/dl and have metastatic lesions to at least two bone sites, with at least one site that has clinically meaningful pain at baseline (≥ 4 on an 11-point intensity scale). Eligible patients will be given two cycles of Sn-117 m-DTPA every 8 weeks or 56 days. Treatment will be administered by slow IV injection over 5-10 min. Retreatment after two cycles is allowed if patients meet the following retreatment criteria. The primary objective is to evaluate the efficacy of Sn-117 m-DTPA on sustained pain response in patients with CRPC metastatic to at least two bone sites and at least one with clinically meaningful pain at baseline (≥ 4 on an 11-point pain intensity scale). Sustained pain response is defined as: 1) achieving pain index ≤ 3 within a 12-week period and 2) maintaining pain index ≤ 3 over a 16-week period. The secondary objectives are: safety and tolerability, measurement of Sn-117 m-DTPA activity by gamma-camera dosimetry scans, therapeutic efficacy, time to the first symptomatic skeletal event, duration of pain response, changes in PSA and ALP levels, patient-reported outcomes and progression free survival and overall survival. Sn-117 m-DTPA is a unique bone-targeting theranostic radiopharmaceutical agent that selectively binds most heavily to bone metastases sites. This study will be the first prospective phase II trial to assess the pain efficacy and anti-tumor activity of Sn-117 m-DTPA in mCRPC with at least one clinically meaningful pain at baseline. ClincialTrials.gov Identifier: NCT04616547.